Effects of endogenous serum neuregulin-1β on morbidity and mortality in patients with heart failure and left ventricular systolic dysfunction

Jennifer Miao, Shi Huang, Yan Ru Su, Carrie A. Lenneman, Meera Wright, Frank E. Harrell, Douglas B. Sawyer, Daniel J. Lenihan

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

Context: Improved left ventricular ejection fraction (LVEF) following administration of recombinant human Neuregulin-1β (NRG), epidermal growth factor (EGF) involved in cardiomyocyte repair/survival, has been observed in patients with systolic heart failure (HF). Methods: Serum NRG was measured by ELISA in 248 patients with NYHA class I–IV HF. Results: NRG exhibited a marginally significant effect on LVEF trajectory over 11 months (p = 0.07). There is no apparent level of NRG that predicts improved survival. Conclusions: There is a potential relationship between serum NRG and improved LVEF, indicating the need to investigate the utility of NRG in predicting HF outcomes, including LVEF maintenance.

Original languageEnglish
Pages (from-to)704-708
Number of pages5
JournalBiomarkers
Volume23
Issue number7
DOIs
StatePublished - Oct 3 2018

Keywords

  • Neuregulin-1
  • cardiomyopathy
  • heart failure
  • left ventricular ejection fraction
  • left ventricular systolic dysfunction

Fingerprint Dive into the research topics of 'Effects of endogenous serum neuregulin-1β on morbidity and mortality in patients with heart failure and left ventricular systolic dysfunction'. Together they form a unique fingerprint.

Cite this